Mark D. Alexander
Partner
Profile
Experience
Honors
News
Insights
Education
Admissions
LinkedIn
{ Bio Portrait }

Contact

TEL NY 212.728.2237
TEL2 CT 860.275.8130
malexander@axinn.com
New York
Download V-Card
Print PDF

Mark Alexander has more than 30 years of experience representing pharmaceutical and life sciences companies, and other clients across a wide range of industries, in complex deal reviews by global regulators and high-stakes antitrust litigation.  

Mark provides sophisticated and practical counsel to help clients navigate the antitrust regulatory process in US, Europe, and China and gain clearance for billion-dollar deals. His experience includes advising Thermo Fisher Scientific in numerous multibillion-dollar deals, including its recent $1.85 billion acquisition of PeproTech Inc.

As lead antitrust litigation counsel, Mark has particularly deep experience in defending clients against claims under Section 7 of the Clayton Act and Section 2 of the Sherman Act. He also has broad commercial litigation and arbitration experience representing clients across a spectrum of industries, including the communications, oil and gas, consumer products, chemicals, and healthcare sectors.

Prior to joining Axinn, Mark practiced in the New York and London offices of Sullivan & Cromwell LLP.

More » « Less

Professional Activities

  • American Bar Association, Section of Antitrust Law
  • Connecticut Bar Association

Experience

Transactions

  • Represented Thermo Fisher Scientific in its $912 million acquisition of CorEvitas.
  • Represented Thermo Fisher Scientific in its $2.6 billion acquisition of The Binding Site.
  • Represented Thermo Fisher Scientific in its $1.85 billion acquisition of PeproTech Inc.
  • Lead antitrust counsel to Centerbridge Partners portfolio company, KIK Custom Products Inc., in its acquisition of NC Brands LP.
  • Represented Thermo Fisher Scientific in its $13.6 billion acquisition of Life Technologies.
  • Represented Thermo Fisher Scientific in its $12.5 billion tender offer for QIAGEN N.V.
  • Represented Johnson Controls in the $2 billion sale of its Scott Safety business to 3M.
  • Represented Thermo Fisher Scientific in its $7.2 billion acquisition of Patheon N.V.
  • Represented McKesson in its $1.4 billion acquisition of CoverMyMeds LLC.
  • Represented Ball Corporation in its $6.85 billion acquisition of Rexam PLC.
  • Represented Thermo Fisher Scientific in its $4.2 billion acquisition of FEI Company.
  • Represented Charles River Laboratories International Inc. in its $585 million acquisition of WIL Research.
  • Represented Thermo Fisher Scientific in its $1.3 billion acquisition of Affymetrix.
  • Represented SunGard Higher Education in its $1.77 billion sale of SunGard Higher Education to Datatel.
  • Represented Cingular in its $41 billion acquisition of AT&T Wireless.

Litigation

  • Represented Watson Laboratories (now Actavis) in obtaining a victory in the US Court of Appeals for the Fourth Circuit that helped expedite the entry of its generic version of Celebrex® to market.
  • Represented national insurance broker Brown & Brown in obtaining summary judgement by the Connecticut Supreme Court dismissing all claims brought by Blumberg Associates Worldwide. Briefed and argued the appeal, resulting in an unanimous affirmance of a district court decision.
  • Represented Watson Laboratories Inc. in securing summary judgment in litigation against the US Food and Drug Administration (FDA) in the US District Court for the District of Columbia.

Honors

  • Best Lawyers in America (2018 – 2023)
  • Cornell Law Review, Symposium Editor
  • American Jurisprudence Awards, Civil Procedure, Criminal Law, and Torts

News

Education

  • JD, cum laude – Cornell Law School (1992)
  • BA – Indiana University (1989)

Admissions

  • Connecticut
  • New York
  • Tennessee
  • U.S. Court of Appeals for the Fourth Circuit
  • U.S. Court of Appeals for the Seventh Circuit
  • U.S. District Court District of Connecticut
  • U.S. District Court Southern District of New York

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.